Analysts Conflicted on These Healthcare Names: Masimo (MASI) and Medtronic (MDT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report) and Medtronic (MDT – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Masimo (MASI)
Needham analyst Michael Matson maintained a Hold rating on Masimo today. The company’s shares closed last Tuesday at $174.69.
According to TipRanks.com, Matson is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Masimo with a $182.40 average price target, representing a 4.2% upside. In a report released today, Piper Sandler also downgraded the stock to Hold with a $180.00 price target.
See the top stocks recommended by analysts >>
Medtronic (MDT)
In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on Medtronic. The company’s shares closed last Tuesday at $96.41.
According to TipRanks.com, Vazquez is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $113.06 average price target, implying a 17.9% upside from current levels. In a report issued on February 12, Barclays also resumed coverage with a Buy rating on the stock with a $116.00 price target.
